Information Provided By:
Fly News Breaks for May 8, 2017
KERX
May 8, 2017 | 08:18 EDT
Maxim analyst Gabrielle Zhou adjusted her revenue estimates for Keryx to include potential label expansion in the U.S. non-dialysis dependent chronic kidney disease population, extended her model projection for Auryxia to 2027 from 2020 and raised her price target accordingly on Keryx to $9 from $7. She keeps a Buy rating on Keryx, noting that while product uptake has been slow, feedback from nephrologists and dialysis providers is positive.
News For KERX From the Last 2 Days
There are no results for your query KERX